beta
Neurogene Inc.

Neurogene Inc.

NGNE
BATS
Shares

$19.95

$0.34

1.73%

Updated 5 Sep 20:00

$6.88

$74.49

52 weeks low/high

About

Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York.

Capitalization

$284.72M

Shares outstanding

14.27M

Sector

Health Care

Industry

Biotechnology

ISIN

US64135M1053

Lot size

100